Indivior Pharmaceuticals, Inc. has announced strong financial results for the third quarter of 2026, showcasing a 13% increase in total net revenue. The company is on the verge of a significant merger with Supernus Pharmaceuticals, which is expected to close on November 2, 2026. This merger is anticipated to reshape the competitive landscape within the pharmaceutical preparations industry.

Indivior reported total net revenue of $356 million for Q3 2026, compared to $314 million in the same period last year. The company’s net income reached a record $137 million, significantly up from $42 million year-over-year. Additionally, total SUBLOCADE net revenue was $267 million, reflecting a 22% increase from $219 million in Q3 2025.

Background

Indivior Pharmaceuticals, Inc. operates in the pharmaceutical preparations sector, specifically focusing on treatments for substance use disorders and central nervous system diseases. The company trades on the Nasdaq under the ticker symbol INDV. It was previously known as Indivior PLC before rebranding in 2014. Recently, the company has been active in filing reports, including an 8-K on October 29, 2026, and a Form 425 on the same day.

What the Filing Says

The recent filing indicates that Indivior achieved a record quarterly adjusted EBITDA of $211 million, up 76% year-over-year. The company’s Chief Executive Officer, Joe Ciaffoni, stated, "In the third quarter, we delivered record SUBLOCADE net revenue and record adjusted EBITDA, reflecting the strength of our business and the disciplined execution of the Indivior Action Agenda."

Impact

These results may positively impact various stakeholders, including investors, employees, and healthcare providers. The merger with Supernus is expected to create a larger entity focused on central nervous system treatments, potentially leading to enhanced product offerings and market reach.

What's Next

The merger with Supernus is anticipated to close on November 2, 2026, after receiving shareholder approval. Following the merger, the combined company will operate under the name Supernus, Inc., trading on the Nasdaq under the ticker symbol SUPN.